【Objective】 To investigate the preparation quality and clinical application effect of pooled platelets with leukocytes reduced. 【Methods】 The quality and clinical effect of the buffy-coated method prepared pooled platelets leukocytes reduced (experimental group, n=40) and apheresis platelets leukocytes reduced (control group, n=40) were compared. 【Results】 The platelet volume (mL), platelet count (×10¹¹), red blood cell contamination (×10⁸) and residual white blood cell (×10⁶) of the experimental group and control group were 278.90±7.92 vs 276.52±8.01, 2.66±0.09 vs 2.66±0.83, 0.54±0.42 vs 0.83±0.84, 0.29±0.54 vs 0.27±0.51, respectively, with no significant difference. The results of bacterial culture were negative, all met the requirements of relevant national standards. In addition, the CCI (×10^3, 24 h) and PPR (%) were 15.11±9.86 vs 14.61±12.55 and 54.23±18.70 vs 61.41±19.09 respectively, with no significant difference, indicating a certain degree of therapeutic effect. 【Conclusion】 The quality and clinical therapeutic effect of pooled platelets leukocytes reduced were consistent with that of apheresis platelets leukocytes reduced.

Objective To discuss the efficacy of Leucogen tablets treatment lessen the hematological reaction and raise the efficacy therapy of interferon in chronic hepatitis B treated with PEG-αinterferon and α interferon.Methods A total of 395 patients with HBeAg-positive chronic hepatitis B (CHB) inpatients from January 2002 to February 2011.Group:All the patients were assigned to A or B according as during the treatment added Leucogen tablets or not.Results ( 1 ) All of 35.9％ patients had neutrophil counts decrease under 1 × 109/L,A group had 29.6％,B had 42.8％ patients,P =0.01 ;neutrophil counts≤0.75 × 109/L A group had 12.6％,B group had 26.4％,P =0.02; neutrophil counts≤ 0.5 × 109/L A group had 4.8 ％,B group had 16.4％,P =0.04.(2) A group had 8.2％ patients interferon-α dose decreased,all the patient finished the period of therapy.B group had 23.3％ patients interferon-α dose decreased,2.1％ of patients had paused.A group had 40.3％ of patients interferon-α beyond conventional dose,B group had only 5.2％.(3)All of 9.8％ patients had hematoblast decrease under 100 × 109/L,A group had 8.7％,B had 11.1％ patients;hematoblast≤ 80 × 109/L A group had 5.3％,B group had 7.9％ ;hematoblast ≤ 50 × 109/L A group had 1.0％,B group had 2.6％.A group had the trend of reducing hematoblast decrease.(4) At the end of therapy A group had 67.4％ patients HBVDNA ＜ 100IU/ml,54.3％ e antigen negative,40.7％ e antigen conversed; B group had 53.9％,41.2％,26.9％,P was respectively 0.02,0.01,0.01.Conclusion Leucogen tablets treatment and prevention interferon-α-related neutrophil counts hematological reaction in CHB treated with a-interferon,and had the trend of reducing interferon-αrelated hematoblast decrease,farther improved the efficacy of α-interferon treatment CHB.